Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
Dapagliflozin is a medicine to treat diabetes. Its mechanism of action is via sodium-glucose
co-transporter 2 (SGLT2) inhibition. In adults with diabetes, use of sodium-glucose
co-transporter 2 inhibitors is associated with moderate weight (fat) loss, in addition to
other health benefits, including decreased blood pressure, decreased inflammation, and
decreased oxidative stress. It is unclear as to whether these health benefits are due to
SGLT2 inhibition per se, or as a secondary effect of weight loss. We wish to compare the
health benefits of dietary counseling for weight loss with and without concomitant use of an
SGLT2 inhibitor.